Evidence for striatal A2A‐D2 heterodimers has led to a new perspective on molecular
mechanisms involved in schizophrenia and Parkinson's disease. Despite the increasing …

In medium-size, spiny striatal neurons of the direct pathway, dopamine D1-and adenosine
A1-receptors are coexpressed and are mutually antagonistic. Recently, a mutation in the …

Adenosine A 2A receptors are predominantly localized on striatopallidal gamma-
aminobutyric acid (GABA) neurons, where they are colocalized with dopamine D 2 receptors …

In the 1980s and 1990s, the concept was introduced that molecular integration in the Central
Nervous System could develop through allosteric receptor–receptor interactions in …

There is considerable evidence of interactions between adenosine A2A receptors and
dopamine D2 receptors in striatal areas, and antagonists of the A2A receptor have been …

Adenosine A2A receptors are a new target for drug development in Parkinson's disease.
Some experimental and clinical data suggest that A2A receptor antagonists can provide …

In the striatum, dopamine D2 receptors are co-localized with adenosine A2A receptors on
the GABAergic neurons of the striopallidal pathway. Moreover, blockade of A2A receptors …

Several studies found in vitro evidence for heteromerization of dopamine D 1 receptors
(D1R) and D 3 receptors (D3R), and it has been postulated that functional D1R-D3R …

BEHAVIOURAL, AND biochemical evidence for the existence of a powerful specific
postsynaptic interaction between adenosine A 1, and dopamine D 1 receptors in the …

The molecular basis for the known intramembrane receptor–receptor interactions among
heptahelical receptors (G protein coupled receptors, GPCR) was postulated to be …